No announcement yet.

The Charcot Project

  • Filter
  • Time
  • Show
Clear All
new posts

    Thanks for your summaries and thoughts Myoak.
    Good to see you back!


      Originally posted by Leenyi View Post
      Thanks for your summaries and thoughts Myoak.
      Good to see you back!
      You are most welcome!

      I love it that researchers are getting closer and closer to establishing a viral cause for MS AND effective treatments directed at a viral cause, such as temelimab.

      KoKo posted this link announcing a trial of temelimab in progressive MS...


      Thank you for posting this KoKo, and Happy Thanksgiving everyone. There are many PwMS who progress w/o relapses and this trial will be important.

      Early in 2019 this drug was named ‘temelimab’, prior to that it was called GNbAC1, they are the same drug.

      The two year “Angel” study involved 3 different doses… 18mg per kg of body weight, 12mg/kg, and 6mg/kg. 18mg was the most effective dose.

      This drug is a game changer in that it allows your body to rebuild myelin by neutralizing the pHERV-W virus and blocking neurodegeneration! Surely, everyone can recognize the implications to MSers of rebuilding myelin!

      QUOTE… “GeNeuro CEO Jesús Martin-Garcia said: “We are extremely pleased with this data, which clearly confirm the robust and consistent effects of temelimab on key MRI markers of neuroprotection, and we are excited by the early signs of clinical benefit.

      “The results of ANGEL-MS confirm the potential of temelimab to act against disease progression, the largest unmet medical need in this indication. It further reinforces our determination to continue the development of temelimab in MS.”

      Temelimab is a humanised, monoclonal antibody designed to mitigate the effect of a certain human endogenous retrovirus (HERV) called pHERV-W, which is found in the brains of MS patients. Neutralising the virus allows the drug to block the neurodegenerative process and restore myelin integrity in MS patients.

      The drug was well-tolerated by the trial participants and there were no dose-limited safety signals." End Quote

      It does appear that viral components may be driving MS as hypothesized by the Charcot Project.
      Last edited by KoKo; 11-29-2019, 09:40 AM. Reason: replaced link to article


        Originally posted by Myoak View Post
        It does appear that viral components may be driving MS as hypothesized by the Charcot Project.
        Due to the coronavirus pandemic enrollment of the ATA188 trial has been temporarily suspended. That is the bad news. But the good news about ATA188 is definitely worth reviewing.

        Dr. Pender’s work in Australia involved taking blood from MS patients, treating it to amp up EBV infection fighting capabilities and reinjecting it. Although a time-consuming effort and limited in number, the results have been spectacular in my view.

        ATA188 is an attempt to accelerate Pender’s process by processing blood from healthy donors and using it as an immediate, or “off the shelf” treatment for MS.
        There is a flurry of research activity by several different biotech companies including Atara who is using ATA188 in trials currently, and several others, Cellectis, Allogene Therapeutics, Precision BioSciences, and CRISPR Therapeutics among them.

        These companies are spending hundreds of millions of dollars in R & D developing very promising treatments not only for MS but for various types of cancer and for organ rejection problems.

        IMO, we are going to see amazing treatments emerge in the next few years for MS, some types of cancer and organ rejection.

        In MS, we are used to this kind of talk and promises and the product ALWAYS falls short of our expectations. IMO, this one is different. And, IMO, here is how it will play out… remember, JMHO…

        ATA188 does not repair damage directly BUT it gives evidence of halting further damage and by doing so provides an indirect route for repair. This means if an MSer’s reserve capacity to re-wire a work around of a damaged area has not been depleted they will recover function according to the reserve capacity they possess. In a young MSer this capacity is often HUGE!

        I believe most of those with MS using ATA188 will not experience disease progression. Again, JMHO. But this is what trials are for… establishing conclusive proof.

        Also, there is no reason to believe the side effects of this treatment will present the onerous problems often experienced with current MS DMT’s.

        This is a very exciting area of development. These companies are definitely onto something, IMO.


          Originally posted by Myoak View Post
          Due to the coronavirus pandemic enrollment of the ATA188 trial has been temporarily suspended.
          I want to keep some things fresh in mind because the next great leap forward in treating MS is at our doorstep, I believe.

          Adoptive T-cell therapy is descriptive of ATA188 and the type of treatment it represents...

          “CONCLUSION. EBV-specific adoptive T cell therapy was well tolerated. Clinical improvement following treatment was associated with the potency of EBV-specific reactivity of the administered T cells. Further clinical trials are warranted to determine the efficacy of EBV-specific T cell therapy in MS.”

          Today this was posted in the UK…

          EBV AND MS

          There are lots of highly suggestive lines of evidence pointing to a possible role for EBV in causing MS:

          Evidence of prior EBV infection is more common among pwMS

          It is exceptionally rare to have MS and not have evidence of prior EBV infection

          Symptomatic (severe) EBV infection (Infectious Mononucleosis – IM) is associated with increased MS risk

          Higher levels of anti-EBV antibodies correlate with higher MS risk

          Higher levels of anti-EBV antibodies correlate with more severe disease if you have MS

          EBV is present in active MS lesions

          There is some overlap between genetic risk factors for MS and genetic risk factors for more severe EBV infection



            Good News...

            Interim data from a Phase 1 dose-escalation clinical trial evaluating ATA188, an off-the-shelf allogeneic Epstein-Barr Virus (EBV) T-cell immunotherapy, in patients with progressive multiple sclerosis… The results were virtually presented at the European Academy of Neurology Congress.

            Two of the six patients in the high-dose cohort showed disease reversal as measured by a scale called EDSS.

            The estimated primary completion date is September 2022.

            ATA188 Clinical Trial

            The company has yet to publish a press release on the data.


              Originally posted by Myoak View Post
              ATA188 Clinical Trial...The company has yet to publish a press release on the data.

              Thanks for the info & link, Myoak. Good to hear from you!


                Thanks Myoak ! Encouraging news and I was feeling quite discouraged before I read your post ! Thanks very much for your continuous vigilance !